Quince Therapeutics, Inc. (QNCX)

NASDAQ: QNCX · IEX Real-Time Price · USD

0.738

+0.013 (1.72%)

At close: Jul 2, 2024, 4:00 PM

0.746

+0.008 (1.08%)

After-hours: Jul 2, 2024, 6:10 PM EDT

Quince Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2017
Selling, General & Admin	17.7	26.01	29.52	17.59	8.95	Upgrade
Research & Development	9.45	25.18	60.8	61.31	30.21	Upgrade
Other Operating Expenses	5.9	0.83	0	0	0	Upgrade
Operating Expenses	33.04	52.02	90.32	78.89	39.17	Upgrade
Operating Income	-33.04	-52.02	-90.32	-78.89	-39.17	Upgrade
Other Expense / Income	-1.46	-0.07	-0.37	-2.04	-2.19	Upgrade
Pretax Income	-31.58	-51.94	-89.95	-76.85	-36.98	Upgrade
Income Tax	-0.2	-0.28	0	0	0	Upgrade
Net Income	-31.39	-51.66	-89.95	-76.85	-36.98	Upgrade
Shares Outstanding (Basic)	37	33	30	29	19	Upgrade
Shares Outstanding (Diluted)	37	33	30	29	19	Upgrade
Shares Change	11.17%	12.71%	1.86%	53.30%	466.06%	Upgrade
EPS (Basic)	-0.84	-1.54	-3.03	-2.63	-1.94	Upgrade
EPS (Diluted)	-0.84	-1.54	-3.03	-2.63	-1.94	Upgrade
Free Cash Flow	-18.36	-44.1	-63.11	-50.87	-33.33	Upgrade
Free Cash Flow Per Share	-0.49	-1.32	-2.12	-1.74	-1.75	Upgrade
EBITDA	-31.26	-51.74	-89.6	-76.52	-36.79	Upgrade
Depreciation & Amortization	0.32	0.2	0.34	0.33	0.19	Upgrade
EBIT	-31.58	-51.94	-89.95	-76.85	-36.98	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).